Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-07-21 Board/Management Inform…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 ,inter alia, to consider and approve the unaudited financial results of the ....
Board/Management Information Classification · 95% confidence The document is a short notice dated July 21, 2023, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for August 3, 2023. The purpose of the meeting includes considering and taking on record the unaudited financial results for the quarter ended June 30, 2023. The document does not contain any financial data or results itself, but merely announces the upcoming board meeting and the agenda. It is a regulatory announcement pursuant to SEBI regulations about a board meeting, not the actual financial report or results. The document length is only 1565 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces a board meeting and agenda items related to financial results.
2023-07-21 English
Acquisition
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges (NSE and BSE) regarding a regulatory update about a merger scheme approved by the National Company Law Tribunal. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosures by listed companies. The document does not contain financial statements, detailed financial data, or comprehensive report content. It is an announcement informing the exchanges and public about a corporate event (merger approval) related to subsidiaries. The document length is only 1994 characters, which is quite short and consistent with a regulatory announcement rather than a full report. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-20 English
NCLT, Mumbai, has approved Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries ....
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the approval of a Scheme of Amalgamation by the National Company Law Tribunal involving subsidiaries of a company in which Lupin Limited holds interest. The document is brief (1991 characters), contains no financial statements or detailed financial data, and serves as an announcement of a corporate event (merger approval) rather than a full report or detailed filing. It does not fit categories like Annual Report, Interim Report, or M&A filings that require detailed documentation. It is a regulatory announcement informing the market about a corporate event, thus best classified under Regulatory Filings (RNS).
2023-07-20 English
Updates
AGM Information Classification · 95% confidence The document is a notice dated July 18, 2023, addressed to stock exchanges regarding a revised Integrated Report for FY 2022-23, referencing compliance with SEBI Listing Regulations. It includes a detailed Notice of the 41st Annual General Meeting (AGM) scheduled for August 3, 2023, with agenda items such as adoption of audited financial statements, dividend declaration, re-appointment of directors, and remuneration approvals. The document contains detailed resolutions and explanatory notes typical of an AGM notice. It does not contain the full annual report or financial statements themselves but serves as the official notice and agenda for the AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2023-07-18 English
Submission of the Revised Integrated Report of the Company for the year ended March 31, 2023, along with the Notice of the Forty-First Annual General Meeting.
AGM Information Classification · 95% confidence The document is a communication addressed to stock exchanges regarding a revised Integrated Report for FY 2022-23, referencing compliance with SEBI Listing Regulations. It includes a detailed Notice of the 41st Annual General Meeting (AGM) with agenda items such as adoption of audited financial statements, dividend declaration, re-appointment of directors, and remuneration approvals. The document contains detailed resolutions and explanatory notes typical of an AGM notice. It does not contain the full annual report or financial statements themselves but rather the notice and agenda for the AGM where such reports will be considered. Therefore, this document is best classified as AGM Information (AGM-R).
2023-07-18 English
Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin's wholly-owned subsidiary has received FDA approval for a generic drug. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4322 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, no audit information, and no detailed report attached or referenced. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit any other specific category.
2023-07-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.